Parkinson's treatment requires managing overlapping deadlines for insurance claims, disability benefits, and medication coverage—each with strict windows that, if missed, can delay therapy for...
Read more →
People newly diagnosed with Parkinson's ask about cures, medication options, and which approaches actually work—here's what the evidence and clinical experience show.
Read more →
July 2026 brings FDA approvals, clinical trial setbacks, and preclinical breakthroughs reshaping Parkinson's treatment strategy across three simultaneous frontiers.
Read more →
Many Parkinson's patients sabotage their own treatment through medication timing errors, poor communication with doctors, and unrealistic expectations about what drugs can do.
Read more →
Where you live shapes your Parkinson's care as much as your diagnosis does, from Medicaid rules to specialist access and appeal deadlines.
Read more →
Cleveland researchers identify a new Parkinson's target while 150 companies race to develop 200 pipeline drugs—here's what's actually changing for patients in 2026.
Read more →
New Parkinson's treatments often have strict eligibility windows. Here's what the 72-hour timeline actually means and how to act on it.
Read more →
Over 200 Parkinson's drugs are now in clinical trials, with FDA approvals and advanced therapies offering new options in 2026.
Read more →
Personalized stem cell therapies for Parkinson's show measurable clinical improvements in early trials, but remain experimental and inaccessible to most patients.
Read more →
Infections, stress, poor sleep, caffeine, heat, and hormonal shifts can all unexpectedly worsen dyskinesia—even if your Parkinson's medication hasn't changed.
Read more →
Essential tremor is treatable, not progressive—the right combination of medication, behavioral strategies, and adaptive equipment often restores independence completely.
Read more →
New medication combinations enhance levodopa's effects while reducing the wearing-off periods and involuntary movements that develop over years of treatment.
Read more →
Deep brain stimulation can reduce essential tremor severity when medications fail, though surgical risks and lifelong device management require careful consideration.
Read more →
FDA-approved deep brain stimulation now offers tremor relief in 60-90% of patients, with wearable closed-loop devices and novel surgical targets expanding treatment options.
Read more →
Ropinirole market expansion projects USD 800 million globally by 2035, creating targeted opportunities for manufacturers in Parkinson's treatment.
Read more →
Deep brain stimulation offers tremor reduction for people who no longer respond to medication, though surgery and lifetime device management come with their own...
Read more →
Parkinson's disease progresses through distinct stages, with treatment options ranging from medications to surgery that can help manage symptoms for years.
Read more →
Parkinson's disease unfolds through progressive stages, each with distinct motor and non-motor symptoms requiring tailored treatment strategies that evolve over time.
Read more →
When medications fail, targeted brain stimulation can reduce essential tremor by 60 to 90 percent, but surgery carries real risks and lifelong maintenance demands.
Read more →
Amneal Pharmaceuticals faces documented legal challenges in 2026, but no verified lawsuit exists about challenging generic Parkinson's medication copies.
Read more →